![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: GALNS |
Gene summary for GALNS |
![]() |
Gene information | Species | Human | Gene symbol | GALNS | Gene ID | 2588 |
Gene name | galactosamine (N-acetyl)-6-sulfatase | |
Gene Alias | GALNAC6S | |
Cytomap | 16q24.3 | |
Gene Type | protein-coding | GO ID | GO:0000323 | UniProtAcc | P34059 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
2588 | GALNS | LZE4T | Human | Esophagus | ESCC | 2.17e-09 | 2.24e-01 | 0.0811 |
2588 | GALNS | LZE8T | Human | Esophagus | ESCC | 2.39e-02 | 9.54e-02 | 0.067 |
2588 | GALNS | LZE20T | Human | Esophagus | ESCC | 4.50e-03 | 1.04e-01 | 0.0662 |
2588 | GALNS | LZE21D1 | Human | Esophagus | HGIN | 1.22e-02 | 1.91e-01 | 0.0632 |
2588 | GALNS | LZE22T | Human | Esophagus | ESCC | 1.29e-05 | 5.01e-01 | 0.068 |
2588 | GALNS | LZE24T | Human | Esophagus | ESCC | 2.55e-08 | 2.41e-01 | 0.0596 |
2588 | GALNS | LZE21T | Human | Esophagus | ESCC | 1.59e-03 | 2.39e-01 | 0.0655 |
2588 | GALNS | P1T-E | Human | Esophagus | ESCC | 5.25e-06 | 2.76e-01 | 0.0875 |
2588 | GALNS | P2T-E | Human | Esophagus | ESCC | 4.54e-12 | 2.14e-01 | 0.1177 |
2588 | GALNS | P4T-E | Human | Esophagus | ESCC | 6.19e-26 | 4.86e-01 | 0.1323 |
2588 | GALNS | P5T-E | Human | Esophagus | ESCC | 1.20e-09 | 2.00e-01 | 0.1327 |
2588 | GALNS | P8T-E | Human | Esophagus | ESCC | 3.77e-27 | 4.88e-01 | 0.0889 |
2588 | GALNS | P9T-E | Human | Esophagus | ESCC | 8.46e-12 | 2.09e-01 | 0.1131 |
2588 | GALNS | P10T-E | Human | Esophagus | ESCC | 6.29e-22 | 3.42e-01 | 0.116 |
2588 | GALNS | P11T-E | Human | Esophagus | ESCC | 4.24e-12 | 5.01e-01 | 0.1426 |
2588 | GALNS | P12T-E | Human | Esophagus | ESCC | 6.20e-26 | 4.84e-01 | 0.1122 |
2588 | GALNS | P15T-E | Human | Esophagus | ESCC | 5.62e-43 | 8.32e-01 | 0.1149 |
2588 | GALNS | P16T-E | Human | Esophagus | ESCC | 3.14e-18 | 3.92e-01 | 0.1153 |
2588 | GALNS | P17T-E | Human | Esophagus | ESCC | 3.17e-04 | 1.85e-01 | 0.1278 |
2588 | GALNS | P19T-E | Human | Esophagus | ESCC | 1.03e-08 | 5.60e-01 | 0.1662 |
Page: 1 2 3 4 5 6 |
![]() |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
Page: 1 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa041426 | Esophagus | HGIN | Lysosome | 33/1383 | 132/8465 | 6.65e-03 | 4.37e-02 | 3.47e-02 | 33 |
hsa0414213 | Esophagus | HGIN | Lysosome | 33/1383 | 132/8465 | 6.65e-03 | 4.37e-02 | 3.47e-02 | 33 |
hsa0414222 | Esophagus | ESCC | Lysosome | 102/4205 | 132/8465 | 5.11e-11 | 7.13e-10 | 3.65e-10 | 102 |
hsa0414232 | Esophagus | ESCC | Lysosome | 102/4205 | 132/8465 | 5.11e-11 | 7.13e-10 | 3.65e-10 | 102 |
hsa041422 | Liver | HCC | Lysosome | 100/4020 | 132/8465 | 2.32e-11 | 4.31e-10 | 2.40e-10 | 100 |
hsa041423 | Liver | HCC | Lysosome | 100/4020 | 132/8465 | 2.32e-11 | 4.31e-10 | 2.40e-10 | 100 |
hsa041425 | Oral cavity | OSCC | Lysosome | 87/3704 | 132/8465 | 1.97e-07 | 1.35e-06 | 6.86e-07 | 87 |
hsa0414212 | Oral cavity | OSCC | Lysosome | 87/3704 | 132/8465 | 1.97e-07 | 1.35e-06 | 6.86e-07 | 87 |
hsa0414221 | Oral cavity | LP | Lysosome | 67/2418 | 132/8465 | 5.13e-08 | 7.77e-07 | 5.01e-07 | 67 |
hsa0414231 | Oral cavity | LP | Lysosome | 67/2418 | 132/8465 | 5.13e-08 | 7.77e-07 | 5.01e-07 | 67 |
Page: 1 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
GALNS | SNV | Missense_Mutation | c.581N>G | p.Phe194Cys | p.F194C | P34059 | protein_coding | deleterious(0.02) | probably_damaging(0.914) | TCGA-B5-A0JY-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | doxorubicin | SD | |
GALNS | SNV | Missense_Mutation | novel | c.1306N>G | p.Thr436Ala | p.T436A | P34059 | protein_coding | tolerated(0.07) | possibly_damaging(0.832) | TCGA-B5-A1MX-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Hormone Therapy | megace | SD |
GALNS | SNV | Missense_Mutation | rs141171091 | c.1475N>T | p.Ala492Val | p.A492V | P34059 | protein_coding | deleterious_low_confidence(0) | possibly_damaging(0.801) | TCGA-B5-A3FA-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
GALNS | SNV | Missense_Mutation | rs398123440 | c.704N>T | p.Thr235Met | p.T235M | P34059 | protein_coding | deleterious(0.03) | probably_damaging(0.993) | TCGA-D1-A101-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
GALNS | SNV | Missense_Mutation | novel | c.1031N>G | p.Asp344Gly | p.D344G | P34059 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-D1-A175-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Chemotherapy | paclitaxel | SD |
GALNS | SNV | Missense_Mutation | c.319N>T | p.Ala107Ser | p.A107S | P34059 | protein_coding | tolerated(0.18) | possibly_damaging(0.794) | TCGA-D1-A17H-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
GALNS | SNV | Missense_Mutation | c.581T>G | p.Phe194Cys | p.F194C | P34059 | protein_coding | deleterious(0.02) | probably_damaging(0.914) | TCGA-DF-A2KV-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
GALNS | SNV | Missense_Mutation | novel | c.1195A>G | p.Lys399Glu | p.K399E | P34059 | protein_coding | deleterious(0) | probably_damaging(0.998) | TCGA-DI-A1BU-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Chemotherapy | paclitaxel | SD |
GALNS | SNV | Missense_Mutation | novel | c.1427A>G | p.Gln476Arg | p.Q476R | P34059 | protein_coding | tolerated(0.37) | benign(0) | TCGA-EO-A22T-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
GALNS | SNV | Missense_Mutation | c.581N>C | p.Phe194Ser | p.F194S | P34059 | protein_coding | tolerated(0.11) | possibly_damaging(0.661) | TCGA-EO-A3B0-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
Page: 1 2 3 4 5 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
2588 | GALNS | DRUGGABLE GENOME, ENZYME | BMN-110 | ELOSULFASE ALFA | ||
2588 | GALNS | DRUGGABLE GENOME, ENZYME | Elosulfase alfa | |||
2588 | GALNS | DRUGGABLE GENOME, ENZYME | elosulfase alfa | |||
2588 | GALNS | DRUGGABLE GENOME, ENZYME | Elosulfase |
Page: 1 |